These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

236 related articles for article (PubMed ID: 23894121)

  • 21. The predictive value of metabolic syndrome for cardiovascular and all-cause mortality: Tehran Lipid and Glucose Study.
    Amouzegar A; Mehran L; Hasheminia M; Kheirkhah Rahimabad P; Azizi F
    Diabetes Metab Res Rev; 2017 Jan; 33(1):. PubMed ID: 27155315
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Prevalence of non-traditional cardiovascular disease risk factors among persons with impaired fasting glucose, impaired glucose tolerance, diabetes, and the metabolic syndrome: analysis of the Third National Health and Nutrition Examination Survey (NHANES III).
    Muntner P; He J; Chen J; Fonseca V; Whelton PK
    Ann Epidemiol; 2004 Oct; 14(9):686-95. PubMed ID: 15380800
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Metabolic syndrome and all-cause mortality, cardiac events, and cardiovascular events: a follow-up study in 25,471 young- and middle-aged Japanese men.
    Kondo T; Osugi S; Shimokata K; Honjo H; Morita Y; Yamashita K; Maeda K; Muramatsu T; Shintani S; Matsushita K; Murohara T
    Eur J Cardiovasc Prev Rehabil; 2011 Aug; 18(4):574-80. PubMed ID: 21450628
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Correlation between insulin resistance and puberty in children with increased cardiometabolic risk].
    Tobisch B; Blatniczky L; Barkai L
    Orv Hetil; 2011 Jul; 152(27):1068-74. PubMed ID: 21676673
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Metabolically healthy obesity, vitamin D, and all-cause and cardiometabolic mortality risk in NHANES III.
    Al-Khalidi B; Kimball SM; Kuk JL; Ardern CI
    Clin Nutr; 2019 Apr; 38(2):820-828. PubMed ID: 29525513
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Mediterranean diet and mortality risk in metabolically healthy obese and metabolically unhealthy obese phenotypes.
    Park YM; Steck SE; Fung TT; Zhang J; Hazlett LJ; Han K; Merchant AT
    Int J Obes (Lond); 2016 Oct; 40(10):1541-1549. PubMed ID: 27339604
    [TBL] [Abstract][Full Text] [Related]  

  • 27. All-Cause and Cardiovascular Mortality Among Koreans: Effects of Obesity and Metabolic Health.
    Sung KC; Ryu S; Cheong ES; Kim BS; Kim BJ; Kim YB; Chung PW; Wild SH; Byrne CD
    Am J Prev Med; 2015 Jul; 49(1):62-71. PubMed ID: 26094228
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Impaired Fasting Glucose Is the Major Determinant of the 20-Year Mortality Risk Associated With Metabolic Syndrome in Nondiabetic Patients With Stable Coronary Artery Disease.
    Younis A; Goldkorn R; Goldenberg I; Geva D; Tzur B; Mazu A; Younis A; Fisman Z; Tannenbaum A; Klempfner R
    J Am Heart Assoc; 2017 Oct; 6(11):. PubMed ID: 29079562
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Differences in cardiovascular risk factors, insulin resistance, and insulin secretion in individuals with normal glucose tolerance and in subjects with impaired glucose regulation: the Telde Study.
    Nóvoa FJ; Boronat M; Saavedra P; Díaz-Cremades JM; Varillas VF; La Roche F; Alberiche MP; Carrillo A
    Diabetes Care; 2005 Oct; 28(10):2388-93. PubMed ID: 16186268
    [TBL] [Abstract][Full Text] [Related]  

  • 30. High risk of cardiovascular mortality in individuals with impaired fasting glucose is explained by conversion to diabetes: the Hoorn study.
    Rijkelijkhuizen JM; Nijpels G; Heine RJ; Bouter LM; Stehouwer CD; Dekker JM
    Diabetes Care; 2007 Feb; 30(2):332-6. PubMed ID: 17259503
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Effects of diet and exercise in preventing NIDDM in people with impaired glucose tolerance. The Da Qing IGT and Diabetes Study.
    Pan XR; Li GW; Hu YH; Wang JX; Yang WY; An ZX; Hu ZX; Lin J; Xiao JZ; Cao HB; Liu PA; Jiang XG; Jiang YY; Wang JP; Zheng H; Zhang H; Bennett PH; Howard BV
    Diabetes Care; 1997 Apr; 20(4):537-44. PubMed ID: 9096977
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Cardiovascular risk profile in individuals with borderline glycemia: the effect of the 1997 American Diabetes Association diagnostic criteria and the 1998 World Health Organization Provisional Report.
    Lim SC; Tai ES; Tan BY; Chew SK; Tan CE
    Diabetes Care; 2000 Mar; 23(3):278-82. PubMed ID: 10868851
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Comprehensive Evaluation of Type 2 Diabetes and Cardiovascular Disease Risk Profiles in Reproductive-Age Women with Polycystic Ovary Syndrome: A Large Canadian Cohort.
    Kazemi M; Pierson RA; Lujan ME; Chilibeck PD; McBreairty LE; Gordon JJ; Serrao SB; Zello GA; Chizen DR
    J Obstet Gynaecol Can; 2019 Oct; 41(10):1453-1460. PubMed ID: 30712903
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Identical anthropometric characteristics of impaired fasting glucose combined with impaired glucose tolerance and newly diagnosed type 2 diabetes: anthropometric indicators to predict hyperglycaemia in a community-based prospective cohort study in southwest China.
    Zhang F; Wan Q; Cao H; Tang L; Li D; Lü Q; Yan Z; Li J; Yang Q; Zhang Y; Tong N
    BMJ Open; 2018 May; 8(5):e019735. PubMed ID: 29743321
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Type II diabetes mellitus and impaired glucose regulation in Caucasian children and adolescents with obesity living in Germany.
    Wabitsch M; Hauner H; Hertrampf M; Muche R; Hay B; Mayer H; Kratzer W; Debatin KM; Heinze E
    Int J Obes Relat Metab Disord; 2004 Feb; 28(2):307-13. PubMed ID: 14724655
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Nonalcoholic fatty liver disease (NAFLD) and associated mortality in individuals with type 2 diabetes, pre-diabetes, metabolically unhealthy, and metabolically healthy individuals in the United States.
    Golabi P; Paik JM; Kumar A; Al Shabeeb R; Eberly KE; Cusi K; GunduRao N; Younossi ZM
    Metabolism; 2023 Sep; 146():155642. PubMed ID: 37380016
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Impact of metabolic syndrome compared with impaired fasting glucose on the development of type 2 diabetes in a general Japanese population: the Hisayama study.
    Mukai N; Doi Y; Ninomiya T; Hata J; Yonemoto K; Iwase M; Iida M; Kiyohara Y
    Diabetes Care; 2009 Dec; 32(12):2288-93. PubMed ID: 19729523
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Impaired fasting glucose and impaired glucose tolerance in rural population of Bangladesh.
    Rahim MA; Azad Khan AK; Nahar Q; Ali SM; Hussain A
    Bangladesh Med Res Counc Bull; 2010 Aug; 36(2):47-51. PubMed ID: 21473200
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Long term prognostic implication of newly detected abnormal glucose tolerance among patients with stable cardiovascular disease: a population-based cohort study.
    Kabootari M; Asgari S; Ghavam SM; Abdi H; Azizi F; Hadaegh F
    J Transl Med; 2021 Jun; 19(1):277. PubMed ID: 34193200
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Cardiovascular morbidity and mortality associated with the metabolic syndrome.
    Isomaa B; Almgren P; Tuomi T; Forsén B; Lahti K; Nissén M; Taskinen MR; Groop L
    Diabetes Care; 2001 Apr; 24(4):683-9. PubMed ID: 11315831
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.